Read the latest insights we've been sharing on LinkedIn
May 28, 2026
ASCO 2026
by Real Endpoints
As 35,000+ oncology professionals head to Chicago this week for hashtag#ASCO26, we'll hear remarkable science — new data, new approvals, new hope.
LinkedIn >
May 15, 2026
Patient Support Services: Are You Building The Right Program?
by Real Endpoints
Financial toxicity is front and center for patients, providers, and manufacturers alike. And yet, too many patient support programs (PSS) are still being built on assumptions rather than insights.
LinkedIn >
April 15, 2026
100% Tariff Announcement on Imported Branded Pharmaceuticals
by Real Endpoints
LinkedIn >
April 3, 2026
RE’s webinar on “Designing Patient Support Services for Impact”
by Real Endpoints
Affording healthcare continues to be a hot topic – if not THE HOT TOPIC – in 2026. Patient Support Services play a crucial role in helping patients start and stay on therapy – and in today’s environment, getting the design right has never been more important. If you want to know more, there’s still time to register for our upcoming webinar, “𝗗𝗲𝘀𝗶𝗴𝗻𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗳𝗼𝗿 𝗜𝗺𝗽𝗮𝗰𝘁,” happening 𝗔𝗽𝗿𝗶𝗹 𝟭𝟲 at 𝟭𝟭𝗮𝗺 𝗘𝗧.
LinkedIn >
December 5, 2025
RE at the 2026 J. P. Morgan Healthcare Conference
by Real Endpoints
Real Endpoints will be meeting at JP Morgan in January with a variety of folks on these and other issues – and would love to sit down with you as well. We can fill you in on what we see as the implications of policy and payer changes on coverage, reimbursement, and patient support; what we’re expecting for 2026; and discuss the specific topics you’re most concerned about.
read full article >
June 7, 2025
Real Endpoints board member Michael Sherman spells out the implications of recent Massachusetts-based GLP-1 coverage decisions for different healthcare stakeholders.
by Real Endpoints
Real Endpoints board member Michael Sherman spells out the implications of recent Massachusetts-based GLP-1 coverage decisions for different healthcare stakeholders. Thing is these implications could also easily apply to any number of drugs in other competitive disease spaces, where there is high budget impact and more than a little uncertainty about clinical benefit.
LinkedIn >